Homburger advises CDR-Life Inc in its USD 76 m Series A Financing

On April 13, 2022, CDR-Life Inc, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, announced the closing of its USD 76 m Series A financing led by Jeito Capital and RA Capital Management, with participation from Omega Funds.

Homburger advised CDR-Life in the transaction. The Homburger team was led by partner Daniel Häusermann and included lead associate Marc Schamaun as well as associates Anna Peter, Daniel Kuhn (all Corporate / M&A), associate Philippe Weber (Tax) and junior associate Lars Schöni. Homburger partner Dieter Gericke served as independent director of CDR-Life until completion of the financing.